We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+61.09%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$96M
AUM Growth
-$68.2M
(-42%)
Cap. Flow
-$86.6M
Cap. Flow
% of AUM
-90.21%
Top 10 Holdings %
Top 10 Hldgs %
77.1%
Holding
33
New
9
Increased
–
Reduced
8
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$7.64M |
| 2 |
IVA
Inventiva
IVA
|
+$6.97M |
| 3 |
Minerva Neurosciences
NERV
|
+$6.15M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$3.91M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$3.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$10.2M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
+$8.17M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$7.37M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Replimune Group
REPL
$859M
| $11.7M | 12.15% |
1,200,000
-2,400,000
| -67% | -$20.4M |
|
|
ABVX
2
Abivax
ABVX
$11.9B
| $9.44M | 9.83% |
+70,000
| New | +$7.64M |
|
|
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
| $7.78M | 8.1% |
168,029
-134,454
| -44% | -$7.37M |
|
|
CMPS
4
CALL
Compass Pathways
CMPS
$1.67B
| $7.59M | 7.91% |
1,100,000
-45,700
| -4% | -$279K |
|
5
AtaiBeckley Inc
ATAI
$2.67B
| $7.01M | 7.3% |
1,713,105
-573,900
| -25% | -$2.71M |
|
|
IVA
6
Inventiva
IVA
$1.09B
| $6.97M | 7.27% |
+1,500,000
| New | +$6.97M |
|
|
7
Minerva Neurosciences
NERV
$199M
| $6.66M | 6.93% |
+1,655,500
| New | +$6.15M |
|
|
8
PUT
Edgewise Therapeutics
EWTX
$4.28B
| $6.2M | 6.46% |
+250,000
| New | +$5.02M |
|
|
9
Praxis Precision Medicines
PRAX
$8.77B
| $5.86M | 6.1% |
+19,882
| New | +$3.7M |
|
|
10
Edgewise Therapeutics
EWTX
$4.28B
| $4.84M | 5.04% |
+195,000
| New | +$3.91M |
|
11
CALL
uniQure
QURE
$2.77B
| $4.79M | 4.99% |
+200,000
| New | +$7.72M |
|
|
EPRX
12
Eupraxia Pharmaceuticals
EPRX
$431M
| $3M | 3.13% |
397,895
-517,105
| -57% | -$3.19M |
|
13
Ovid Therapeutics
OVID
$455M
| $2.91M | 3.03% |
+1,785,000
| New | +$2.75M |
|
|
14
CALL
Taysha Gene Therapies
TSHA
$1.71B
| $2.75M | 2.86% |
+500,000
| New | +$2.43M |
|
|
15
Taysha Gene Therapies
TSHA
$1.71B
| $2.51M | 2.62% |
457,132
-1,440,980
| -76% | -$7M |
|
16
Solid Biosciences
SLDB
$858M
| $2.33M | 2.43% |
413,625
-135,557
| -25% | -$735K |
|
|
WHWK
17
Whitehawk Therapeutics
WHWK
$192M
| $1.98M | 2.06% |
817,939
| – | – |
|
18
ProMIS Neurosciences
PMN
$136M
| $1.7M | 1.77% |
249,339
-1
| -0% | -$10 |
|
19
Amylyx Pharmaceuticals
AMLX
$1.97B
| – | – |
-437,391
| Closed | -$5.94M |
|
20
Arcutis Biotherapeutics
ARQT
$3.56B
| – | – |
-233,220
| Closed | -$4.4M |
|
|
21
Ascendis Pharma A/S
ASND
$17.1B
| – | – |
-51,080
| Closed | -$10.2M |
|
22
Avalo Therapeutics
AVTX
$1.02B
| – | – |
-178,100
| Closed | -$2.26M |
|
|
CMPS
23
Compass Pathways
CMPS
$1.67B
| – | – |
-1,026,382
| Closed | -$6.26M |
|
|
24
Madrigal Pharmaceuticals
MDGL
$12.8B
| – | – |
-32,662
| Closed | -$15M |
|
25
CALL
MoonLake Immunotherapeutics
MLTX
$1.64B
| – | – |
-69,000
| Closed | -$495K |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2025 Portfolio in Review
As of Q4 2025, Ally Bridge Group held 33 positions worth $96M, down 42% from $164M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Ally Bridge Group withdrew a net $86.6M in Q4 2025, closing 15 positions and reducing 8 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 73% a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Abivax worth $9.44M.
- Ally Bridge Group's largest Q4 2025 buy was Abivax: 70,000 shares worth $9.44M.
- Ally Bridge Group's biggest Q4 2025 reduction was Soleno Therapeutics, cutting an estimated $7.37M.
- Ally Bridge Group fully exited Madrigal Pharmaceuticals in Q4 2025, selling an estimated $15M.
- Ally Bridge Group's ten largest holdings make up 77% of its $96M portfolio in Q4 2025.
- Ally Bridge Group opened 9 new positions and closed 15 in Q4 2025.
- Ally Bridge Group's portfolio value fell 42% quarter-over-quarter to $96M.
Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.